Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2783

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2783). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Divalproex Sodium De Figure 1)

Chemical structure diagram of divalproex sodium, illustrating the molecular arrangement including sodium ion, carboxylate groups, and hydrocarbon chains, consistent with its chemical identity as an active pharmaceutical ingredient.*

FDA Label Image

Figure1 (Divalproex Sodium De Figure 2)

A bar chart comparing percentages (%) between a placebo (PBO) and divalproex sodium (DVPX) across two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX. Study 2 (MRS) shows 29% for PBO and 58% for DVPX. The vertical axis represents percentage values.*

FDA Label Image

Figure2 (Divalproex Sodium De Figure 3)

A cumulative distribution graph showing the percentage reduction in complex partial seizure (CPS) rate among patients treated with divalproex sodium compared to placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate, with an upward arrow indicating improvement and downward indicating worsening.*

FDA Label Image

Figure3 (Divalproex Sodium De Figure 4)

A line graph depicting the percentage reduction in CPR rate versus the percentage of patients. It compares high dose and low dose treatments, with high dose represented by a solid line and low dose by a dashed line. The vertical axis indicates improvement or worsening, and the horizontal axis shows the percentage of patients from 0% to 100%.*

FDA Label Image

Figure4 (Divalproex Sodium De Figure 5)

A bar chart comparing the effects of placebo and divalproex sodium across two studies. The x-axis displays Study 1 and Study 2 groups, each with placebo and divalproex sodium bars, while the y-axis measures an unspecified variable ranging from 0 to 6. The chart shows higher values for placebo compared to divalproex sodium in both studies.*

FDA Label Image

Label (Lbl713352783)

Label for divalproex sodium delayed release tablets USP, 250 mg strength. The label includes NDC 71335-2783 and indicates a package size of 30 tablets. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by OrBion Pharmaceuticals Private Ltd. Storage instructions and dispensing information are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.